Table 2.
Summary of SARS-CoV-2 clearance rates.
|
p valueb |
||||||
|---|---|---|---|---|---|---|
| Novaferon (N = 30) | LPV/ra + Novaferon (N = 30) | LPV/r (N = 29) | LPV/r vs. Novaferon | LPV/r vs. LPV/r + Novaferon | Novaferon vs. LPV/r + Novaferon | |
| Day 3 | 16.7% (5/30) | 36.7% (11/30) | 10.3% (3/29) | 0.4783 | 0.0175 | 0.0798 |
| Day 6 | 50.0% (15/30) | 60.0% (18/30) | 24.1% (7/29) | 0.0400 | 0.0053 | 0.4363 |
| Day 9 | 56.7% (17/30) | 70.0% (21/30) | 51.7% (15/29) | 0.7032 | 0.1502 | 0.2839 |
a
LPV/r: Lopinavir/Ritonavir.
b
p values for comparisons between treatment groups using Chi-square test; At any visit, missing viral RNA outcome was imputed with Last Observation Carried Forward (LOCF) method.